AMG National Trust Bank Buys New Holdings in Sanofi $SNY

AMG National Trust Bank purchased a new position in Sanofi (NASDAQ:SNY) during the 1st quarter, HoldingsChannel reports. The institutional investor purchased 56,427 shares of the company’s stock, valued at approximately $2,719,000.

Several other institutional investors and hedge funds have also bought and sold shares of the business. Morgan Stanley boosted its holdings in shares of Sanofi by 20.4% in the 4th quarter. Morgan Stanley now owns 9,102,196 shares of the company’s stock valued at $441,093,000 after acquiring an additional 1,540,271 shares during the last quarter. Invesco Ltd. raised its holdings in shares of Sanofi by 5.4% during the fourth quarter. Invesco Ltd. now owns 6,110,874 shares of the company’s stock worth $296,133,000 after purchasing an additional 313,327 shares during the last quarter. Raymond James Financial Inc. lifted its position in Sanofi by 81.3% during the second quarter. Raymond James Financial Inc. now owns 5,879,894 shares of the company’s stock valued at $284,058,000 after purchasing an additional 2,635,867 shares during the period. Franklin Resources Inc. lifted its position in Sanofi by 29.7% during the fourth quarter. Franklin Resources Inc. now owns 5,100,097 shares of the company’s stock valued at $247,151,000 after purchasing an additional 1,168,339 shares during the period. Finally, Mondrian Investment Partners LTD boosted its holdings in Sanofi by 23.5% in the fourth quarter. Mondrian Investment Partners LTD now owns 4,495,348 shares of the company’s stock valued at $217,845,000 after purchasing an additional 856,742 shares during the last quarter. 14.03% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

SNY has been the topic of several analyst reports. BNP Paribas Exane downgraded Sanofi from an “outperform” rating to a “neutral” rating and set a $50.00 price target on the stock. in a research report on Monday, April 20th. Citigroup restated a “neutral” rating on shares of Sanofi in a research note on Monday, April 13th. Morgan Stanley set a $49.00 target price on Sanofi in a report on Wednesday, July 8th. Sanford C. Bernstein upgraded Sanofi to a “strong-buy” rating in a research report on Thursday, March 19th. Finally, Weiss Ratings upgraded Sanofi from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Wednesday, May 13th. Two research analysts have rated the stock with a Strong Buy rating, three have issued a Buy rating and ten have issued a Hold rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus target price of $49.50.

Sanofi Stock Performance

NASDAQ SNY opened at $43.18 on Wednesday. The stock has a market capitalization of $104.69 billion, a price-to-earnings ratio of 12.06, a PEG ratio of 1.12 and a beta of 0.34. The stock has a 50-day moving average of $43.30 and a 200 day moving average of $45.59. The company has a current ratio of 1.01, a quick ratio of 0.22 and a debt-to-equity ratio of 0.17. Sanofi has a twelve month low of $40.89 and a twelve month high of $52.68.

Sanofi Profile

Sanofi (NASDAQ:SNY) is a multinational pharmaceutical company headquartered in France that researches, develops, manufactures and markets prescription medicines, vaccines and consumer healthcare products. The company operates across multiple therapeutic areas, including immunology, rare diseases, oncology, cardiovascular and metabolic diseases, and vaccines through its Sanofi Pasteur division. Sanofi sells products to hospitals, clinics, governments and retail pharmacies, with a broad global footprint and significant presence in Europe, North America and emerging markets.

Key commercial offerings include specialty biologics and established small-molecule medicines.